AssetMark Inc’s Protagonist Therapeutics PTGX Stock Holding History

AssetMark Inc’s Portfolio PTGX Stock Details PTGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$12.1M	Buy	98,687 +52,245	+112%	+$5.46M	0.02%	511
2026 Q1	$4.89M	Buy	46,442 +46,157	+16,195%	+$4.09M	0.01%	667
2025 Q4	$24.9K	Buy	285 +5	+2%	+$409	﹤0.01%	1932
2025 Q3	$18.6K	Sell	280 -10	-3%	-$568	﹤0.01%	1940
2025 Q2	$16K	Sell	290 -5	-2%	-$240	﹤0.01%	1857
2025 Q1	$14.3K	Buy	295 +50	+20%	+$2.1K	﹤0.01%	1772
2024 Q4	$9.46K	Buy	245 +80	+48%	+$3.49K	﹤0.01%	1800
2024 Q3	$7.42K	Buy	+165	New	+$6.67K	﹤0.01%	1674
2018 Q1	–	Sell	-20	Closed	–	–	1857
2017 Q4	$0	Buy	+20	New	+$355	﹤0.01%	2074

Other funds holding PTGX

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

NFT

Nan Fung Trinity Central, Hong Kong, Hong Kong $1.01B AUM 64.38% 1-Year Est. Return

MAP

Moody Aldrich Partners Marblehead, Massachusetts $557M AUM 122.79% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return

SOADOR

State of Alaska Department of Revenue Juneau, Alaska $10.1B AUM 42.83% 1-Year Est. Return

LSERS

Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.74B AUM 53.06% 1-Year Est. Return

New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

ETC

Exchange Traded Concepts Oklahoma City, Oklahoma $21.9B AUM 68.6% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

AssetMark Inc's PTGX Position: Q2 2026 in Review

AssetMark Inc increased its Protagonist Therapeutics (PTGX) stake by 112% in Q2 2026, buying an estimated $5.46M and bringing the position to 98,687 shares worth $12.1M. The position accounts for 0.02% of the portfolio, ranked #511.

AssetMark Inc first reported a position in PTGX in Q4 2017 and has held it in 9 quarters since. 74 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

AssetMark Inc held 98,687 shares of Protagonist Therapeutics worth $12.1M as of Q2 2026.
AssetMark Inc bought 52,245 Protagonist Therapeutics shares in Q2 2026, an estimated $5.46M.
Protagonist Therapeutics made up 0.02% of AssetMark Inc's portfolio in Q2 2026, its #511 holding.
AssetMark Inc first reported a position in Protagonist Therapeutics in Q4 2017 and has held it in 9 quarters since.
74 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on AssetMark Inc's 13F filing for Q2 2026, filed 30 Jul 2026.